Kura Oncology (NASDAQ:KURA) Insider Teresa Brophy Bair Sells 31,487 Shares

Kura Oncology, Inc. (NASDAQ:KURA) insider Teresa Brophy Bair sold 31,487 shares of Kura Oncology stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total transaction of $397,680.81. Following the completion of the sale, the insider directly owned 195,444 shares in the company, valued at approximately $2,468,457.72. The trade was a 13.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Kura Oncology Trading Up 1.5%

NASDAQ KURA opened at $11.89 on Friday. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $1.06 billion, a P/E ratio of -3.53 and a beta of 0.38. Kura Oncology, Inc. has a 52-week low of $7.36 and a 52-week high of $12.90. The firm has a 50-day moving average price of $10.53 and a 200 day moving average price of $9.46.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. The company had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. Equities research analysts expect that Kura Oncology, Inc. will post -3.23 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on KURA. CLSA set a $24.00 price objective on Kura Oncology in a research report on Thursday, June 4th. Wall Street Zen raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Finally, Sanford C. Bernstein set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, June 15th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.62.

Institutional Trading of Kura Oncology

Institutional investors have recently bought and sold shares of the company. IFP Advisors Inc grew its holdings in Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after purchasing an additional 1,284 shares during the last quarter. Allworth Financial LP boosted its position in shares of Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after buying an additional 1,553 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock valued at $60,000 after acquiring an additional 1,888 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after acquiring an additional 9,958 shares in the last quarter. Finally, Brevan Howard Capital Management LP purchased a new position in Kura Oncology during the 2nd quarter valued at about $80,000.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.